VIR (Vir Biotechnology, Inc. Common Stock) Stock Analysis - Financials

Vir Biotechnology, Inc. Common Stock (VIR) is a publicly traded Healthcare sector company. As of May 21, 2026, VIR trades at $9.08 with a market cap of $1.48B and a P/E ratio of -2.83. VIR moved +4.10% today. Year to date, VIR is +53.37%; over the trailing twelve months it is +87.74%. Its 52-week range spans $4.16 to $14.45. Analyst consensus is strong buy with an average price target of $20.63. Rallies surfaces VIR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are VIR's key financials?

VIR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VIR recently traded at $9.08. Market cap is $1.48B. P/E ratio is -2.83. Revenue is $65.50M.

VIR Key Metrics

Key financial metrics for VIR
MetricValue
Price$9.08
Market Cap$1.48B
P/E Ratio-2.83
EPS$-3.12
Dividend Yield0.03%
52-Week High$14.45
52-Week Low$4.16
Volume24
Avg Volume0
Revenue (TTM)$65.50M
Net Income$-442.72M
Gross Margin0.00%

VIR Annual Financials

YearRevenueNet IncomeEPS
2025$68.56M$-437.99M$-3.16
2023$86.18M$-615.12M$-4.59
2022$1.62B$515.84M$3.89
2021$1.10B$528.58M$4.07

Latest VIR News

Recent VIR Insider Trades

  • SATO VICKI L sold 22.00K (~$221.03K) on May 1, 2026.
  • De Backer Marianne sold 72.56K (~$664.35K) on Apr 6, 2026.
  • SATO VICKI L sold 22.00K (~$199.62K) on Apr 1, 2026.

VIR Analyst Consensus

9 analysts cover VIR: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.63.

Common questions about VIR

What are VIR's key financials?
VIR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VIR recently traded at $9.08. Market cap is $1.48B. P/E ratio is -2.83. Revenue is $65.50M.
Is VIR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VIR. It does not provide personalized investment advice.
VIR

VIR